Income Statement
AUTOLUS THERAPEUTICS PLC
AUTL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
75.39 | 10.12 | 1.70 |
|
Cost of Revenue
|
96.37 | 11.39 | - |
|
Gross Profit
|
-20.98 | -1.27 | 1.70 |
|
Operating Expenses
|
-192.74 | 239.52 | 177.23 |
|
Research & Development
|
117.69 | 138.44 | 130.48 |
|
Selling, General & Administrative
|
131.87 | 101.09 | 46.75 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-270.54 | -240.79 | -175.53 |
|
Non-Operating Income
|
-15.01 | 22.29 | -28.70 |
|
Interest Income
|
18.98 | 32.36 | 13.51 |
|
Interest Expense
|
36.67 | 9.29 | 45.07 |
|
Other Non-Op Income / Expense
|
0.52 | 0.22 | 2.86 |
|
Income Before Tax
|
-285.56 | -219.13 | -208.40 |
|
Income Tax Expense
|
1.97 | 1.53 | -0.02 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-287.53 | -220.66 | -208.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-262.25 | -233.24 | -168.96 |
|
Earnings Per Share (Basic)
|
-1.08 | -0.86 | -1.20 |
|
Diluted EPS
|
-1.08 | -0.86 | -1.20 |
|
Weighted Average Shares
|
266.14 | 255.16 | 173.94 |
|
Diluted Weighted Avg Shares
|
266.14 | 255.16 | 173.94 |
|
Comprehensive Income
|
-263.71 | -220.84 | -198.48 |